Lenacapavir sodium

来那帕韦钠

Report date: 2026/05/26 20:00:28
NMEFirst In Class

Base Information

Drug NameLenacapavir sodium
Drug Alias NameLenacapavir来那帕韦SUNLENCAYeztugo萨兰卡 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCapsid protein inhibitors
TargetsCapsid protein
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryEU
Original Approved Date2022/08/17
Country/TerritoryCanadaUnited StatesTaiwan +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGilead Inc
China Registration ClassN/A

Develop Information

Active CompaniesGilead Sciences IncGilead Sciences Ireland Uc
Inactive CompaniesRottendorf Pharma GmbhNational Institute Of Allergy And Infectious Diseases (Niaid)Gilead Sciences Shanghai Pharmaceutical Technology Co Ltd
Active IndicationsHIV Infections
Inactive IndicationsN/A

Other Information

ATC CodeJ05AE
Related LinksWikipediaDrugBankKEGG